Speaking Pain interventions
What the Evidence Actually Says About Regenerative Pain Interventions
PRP, bone marrow concentrate, stem cells and prolotherapy are marketed faster than they are tested. Here is what the trials show.
Regenerative treatments are among the most requested and least understood options in pain care. Drawing on a structured review of randomized trials, systematic reviews and 2026 society guidance, Dr. Kao walks condition by condition through knee and hip osteoarthritis, tendinopathies, plantar fasciitis, rotator cuff disease and disc-related back pain. The talk separates what improves pain from what changes tissue, explains why clinic marketing is not regulatory approval, and offers a practical framework for discussing these options with patients.
Attendees will be able to
- Summarize the trial evidence for PRP, BMAC, mesenchymal stromal cells, adipose preparations and dextrose prolotherapy by condition
- Distinguish symptom relief from evidence of tissue regeneration
- Separate US regulatory and marketing status from proof of efficacy
- Apply a structured approach to counseling patients who ask about regenerative treatments